Determination of itraconazole and hydroxyitraconazole in plasma by use of liquid chromatography-tandem mass spectrometry with on-line solid-phase extraction

Clinical Chemistry and Laboratory Medicine

Volumn 41, Issue 7, 2003, Pages 915-920

  Vogeser, Michael ^a   Spöhrer, Ute ^a   Schiel, Xaver ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Hydroxyitraconazole; Itraconazole; Liquid chromatography tandem mass spectrometry

Indexed keywords

4 [4 [4 [4 [[2 (2,4 DICHLOROPHENYL) 2 (1H 1,2,4 TRIAZOL 1 YLMETHYL) 1,3 DIOXOLAN 4 YL]METHOXY]PHENYL] 1 PIPERAZINYL]PHENYL] 2,4 DIHYDRO 2 (3 METHYLBUTYL) 3H 1,2,4 TRIAZOL 3 ONE; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; CARBAMAZEPINE; CYCLOSPORIN; DRUG METABOLITE; ERYTHROMYCIN; HYDROXYITRACONAZOLE; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; ISONIAZID; ITRACONAZOLE; MACROLIDE; NEVIRAPINE; PHENYTOIN; PROTEINASE INHIBITOR; RIFABUTIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CHEMOPROPHYLAXIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG MONITORING; DRUG STRUCTURE; HOSPITAL LABORATORY; HUMAN; LIQUID CHROMATOGRAPHY; MYCOSIS; NONHUMAN; ONLINE SYSTEM; PRIORITY JOURNAL; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; VERTIGO;

ANTIFUNGAL AGENTS; AUTOMATION; CHROMATOGRAPHY, LIQUID; HUMANS; ITRACONAZOLE; MASS SPECTROMETRY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 0041472496     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2003.139     Document Type: Article

References (32)

1. Vogeser M, Wanders A, Haas A, Ruckdeschel G. A four-year review of fatal Aspergillosis. Eur J Clin Microbiol Infect Dis 1999; 18:42-5.
2. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32:358-66.
3. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730-51.
4. Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, Girmenia C, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 1999; 28:250-5.
5. Boogaerts M, Maertens J, van Hoof A, de Bock R, Fillet G, Peetermans M, et al. Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. J Antimicrob Chemother 2001; 48:97-103.
6. Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, SchwarerAP, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001; 135:412-22.
7. Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001; 33:e83-90.
8. Vandewoude K, Vogelaers D, Decruyenaere J, Jaqmin P, De Beule K, Van Peer A, et al. Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob Agents Chemother 1997; 41:2714-8.
9. Boogaerts MA, Maertens J, Van Der Geest R, Bosly A, Michaux JM, Van Hoof A, et al. Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. Antimicrob Agents Chemother 2001; 45:981-5.
10. Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989; 32 Suppl 1:67-87.
11. Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37:310-44.
12. Odds FC, Bossche HV. Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro. J Antimicrob Chemother 2000; 45:371-3.
13. Adriaenssens B, Roskams T, Steger P, Van Steenbergen W. Hepatotoxicity related to itraconazole: report of three cases. Acta Clin Belgica 2001; 56:364-9.
14. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997; 24:235-47.
15. Poirier JM, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet 1998; 35:461-73.
16. Glasmacher A, Hahn C, Leutner C, Molitor E, Wardelmann E, Losem C, et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999; 42:443-51.
17. Boogaerts M, Maertens J. Clinical experience with itraconazole in systemic fungal infections. Drugs 2001; 61 Suppl 1:39-47.
18. Woestenborghs R, Lorreyne W, Heykants J. Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography. J Chromatogr 1987; 413:332-7.
19. Allenmark S, Edebo A, Lindgren K. Determination of itraconazole in serum with high-performance liquid chromatography and fluorescence detection. J Chromatogr 1990; 532:203-6.
20. Badcock NR. Micro-scale method for itraconazole in plasma by reversed-phase high-performance liquid chromatography. J Chromatogr 1990; 525:478-83.
21. Poirier JM, Lebot M, Descamps P, Levy M, Cheymol G. Determination of itraconazole and its active metabolite in plasma by column liquid chromatography. Ther Drug Monit 1994; 16:596-601.
22. Darouiche RO, Setoodeh A, Anaissie EJ. Potential use of a simplified method for determination of itraconazole levels in plasma and esophageal tissue by using high-performance liquid chromatography. Antimicrob Agents Chemother 1995; 39:757-9.
23. Lacroix C, Wojciechowski F, Danger P. Simultaneous determination of itraconazole, hydroxy-itraconazole and amphotericin B in human plasma by HPLC with photodiode array detection. Ann Biol Clin 1995; 53:293-7.
24. Rifai N, Sakamoto M, Platt O, Brugnara C. A high-performance liquid chromatographic assay for the determination of itraconazole concentration using solid-phase extraction and small sample volume. Ther Drug Monit 1995; 17:522-5.
25. Compas D, Touw DJ, de Goede PN. Rapid method for the analysis of itraconazole and hydroxyitraconazole in serum by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1996; 687:453-6.
26. Ng TK, Chan RC, Adeyemi-Doro FA, Cheung SW, Cheng AF. Rapid high performance liquid chromatographic assay for antifungal agents in human sera. J Antimicrob Chemother 1996; 37:465-72.
27. Gubbins PO, Gurley BJ, Bowman J. Rapid and sensitive high performance liquid chromatographic method for the determination of itraconazole and its hydroxy-metabolite in human serum. J Pharm Biomed Anal 1998; 16:1005-12.
28. Carrier A, Parent J. Liquid chromatographic-mass spectrometric determination of itraconazole and its major metabolite, hydroxyitraconazole, in dog plasma. J Chromatogr B Biomed Sci Appl 2000; 745:413-20.
29. Al-Rawithi S, Hussein R, Al-Moshen I, Raines D. Expedient microdetermination of itraconazole and hydroxyitraconazole in plasma by high-performance liquid chromatography with fluorescence detection. Ther Drug Monit 2001; 23:445-8.
30. Yao M, Chen L, Srinivas NR. Quantitation of itraconazole in rat heparinized plasma by liquid chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 2001; 752:9-16.
31. Koks CH, Sparidans RW, Lucassen G, Crommentuyn KM, Beijnen JH. Selective high-performance liquid chromatographic assay for itraconazole and hydroxyitraconazole in plasma from human immunodeficiency virus-infected patients. J Chromatogr B Biomed Sci Appl 2002; 767:103-10.
32. Vogeser M, Zachoval R, Spöhrer U, Jacob K. Potential lack of specificity using electrospray tandem-mass spectrometry for the analysis of mycophenolic acid in serum. Therapeutic Drug Monit 2001; 23:722-4.